National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing,P.R. China.
Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing,P.R. China.
Hum Vaccin Immunother. 2023 Dec 15;19(3):2283315. doi: 10.1080/21645515.2023.2283315. Epub 2023 Nov 20.
Hypertension, a prevalent chronic disease, has been associated with increased COVID-19 severity. To promote the COVID-19 booster vaccination of hypertensive patients, this study investigated the willingness to receive boosters and the related influencing factors based on the health belief model (HBM model). Between June and October 2022, 453 valid questionnaires were collected across three Chinese cities. The willingness to receive a booster vaccination was 72.2%. The main factors that influenced the willingness of patients with hypertension to receive a booster shot were male (χ = 7.008, = .008), residence in rural (χ = 4.778, = .029), being in employment (χ = 7.232, = .007), taking no or less antihypertensive medication (χ = 9.372, = .025), with less hypertension-related comorbidities (χ = 35.888, < .0001), and did not have any other chronic diseases (χ = 28.476, < .0001). Amid the evolving COVID-19 landscape, the willingness to receive annual booster vaccination was 59.4%, and employment status (χ = 10.058, = .002), and presence of other chronic diseases (χ = 14.256, < .0001) are associated with the willingness of annual booster vaccination. Respondents with higher perceived severity, perceived benefits, perceived self-efficacy, and lower perceived barriers were more willing to receive booster shots. The mean and median value of willingness to pay (WTP) for a dose of booster were 53.17 CNY and 28.31 CNY. Concerns regarding booster safety and the need for professional advice were prevalent. Our findings highlight the importance of promoting booster safety knowledge and health-related management among hypertensive individuals through professional organizations and medical specialists.
高血压是一种常见的慢性疾病，与 COVID-19 严重程度增加有关。为促进高血压患者接种 COVID-19 加强针，本研究基于健康信念模型（HBM 模型）调查了他们接种加强针的意愿及其相关影响因素。2022 年 6 月至 10 月，在中国三个城市共收集了 453 份有效问卷。患者接种加强针的意愿为 72.2%。影响高血压患者接种加强针意愿的主要因素是男性（χ²=7.008， =0.008）、农村居住（χ²=4.778， =0.029）、在职（χ²=7.232， =0.007）、服用降压药较少或不服药（χ²=9.372， =0.025）、高血压相关合并症较少（χ²=35.888， <0.0001）、无其他慢性病（χ²=28.476， <0.0001）。在 COVID-19 不断演变的情况下，每年接种加强针的意愿为 59.4%，就业状况（χ²=10.058， =0.002）和其他慢性病的存在（χ²=14.256， <0.0001）与每年接种加强针的意愿相关。认为严重性更高、益处更大、自我效能感更高、障碍更小的受访者更愿意接种加强针。对一剂加强针的支付意愿（WTP）的平均值和中位数分别为 53.17 元和 28.31 元。对加强针安全性的担忧和对专业建议的需求普遍存在。研究结果强调了通过专业组织和医学专家向高血压患者宣传加强针安全性知识和相关健康管理的重要性。
